Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Tumor Imaging We have a lot of selections for Tumor Imaging Tumor is more metabolic active. Tumor has specific receptors. 131I-MIBG, 131I-anti-AFP-MoAb Tumor can cause function and structure changes. 18F-FDG, 18F-FLT, 11C-acetate, 11C-cholin, 201Tl, 99mTc-MIBI. BBB destruction, 99mTc-PMT Tumor has specific gene expressions antisense imaging 18F-FDG PET Pheochromocytoma of right adrenal gland Bone metastasis of malignant tumor Imaging for BBB Destruction Objectives of This Part FDG PET imaging mechanism, imaging agent, image interpretation, clinical indications and usage. 67Ga imaging imaging agent, image interpretation, clinical indications and usage. Importance: ***, **, * FDG PET imaging Imaging agent: 18F-FDG Imaging instrument: PET/CT or PET Imaging procedure: starvation for over 6h 18F-FDG injection wait 40-50 min acquisition on PET/CT image reconstruction Molecular Mechanism Tumor Cell Vascular Glycogen 18FDG-1-P Hexokinase K1 18FDG 18FDG-6- K3 18FDG K2 18FDG-6P K4 Glucose-6phosphatase phosphogluconolactone 18F-fru-6-P Glucose transporter protein Glycolysis HMP shunt Molecular Mechanism Normal Image Coronal images of PET CT, PET and fusion image Quantitative Parameters of PETFDG Response Standardized uptake value (SUV) Uptake in tumor, normalized for dose injected and weight of the patient Obtained as primary response parameter on every lesion SUV = (decay corrected dose/cc of tumor) (injected dose/patient weight (g)) Clinical Indications Early detect and differentiate tumor. Tumor staging and restaging. Define tumor scope, especially for radiotherapy planning. Therapy response monitoring. Early differentiate regression or radiation necrosis. Lead to correct treatment, save medical expenses. FDG PET could detect tumors in their early stage and can be used for tumor screen Gastric carcinoma found in FDG PET tumor screen FDG PET can differentiate benign and malignant lesion more effectively. Carcinoma of gallbladder Carcinoma of rectum nasopharyngeal carcinoma Lymphoma Post operative scar of left lung Brain Tumor CP 696483 High Grade recurrence post RT PET FDG TRANSAXIAL 5 Oct 2000 T-1 POST Gd FDG PET can stage tumor more accurately Lymph node metastasis of lung carcinoma,CT is negative,but is positive in PET FDG PET can monitoring early therapeutic response and predict outcome. after chemo Before Chemo SUV=4.6 Gallium-67 for Infection / Inflammation produced by cyclotron. The half life of gallium-67 is 78 hours. decays by electron capture. Gallium-67 photopeaks Energy Abundance 93 keV 40% 184 keV 20% 300 keV 17% 393 keV 5% Physiology Ga-67 acts as an iron analogue. Initially it binds to transferrin. The complex diffuses through loose endothelial junctions of capillaries at sites of inflammation and enters the extracellular fluid. Leukocytes migrate to sites of inflammation and degranulate, releasing large quantities of lactoferrin. Ga-67 has higher affinity for lactoferrin than transferrin. Ga-67 also attaches to siderophores of bacteria. Therefore can be used in leukopenic patients with bacterial infection and in detecting sterile abscesses that provoke a leukocyte response. Areas where Ga-67 normally localizes liver (site of highest uptake) bone marrow spleen salivary glands nasopharynx lacrimal glands breast uptake (especially in pregnant and lactating women) kidneys and bladder in the first 24 hours faint uptake can still be normal for up to 72 hours mild diffuse lung uptake at 24 hours or less Technique Common injection doses range from 3-6 mCi. Imaging should not usually be sooner than 24 hours - high background at this time produces false negatives. Common Indications of gallium-67 imaging (1) Whole-body survey to localize source of fever in patients with Fever of Unknown Origin (FUO). Detection of pulmonary and mediastinal inflammation/infection, especially in the immunocompromised patient. Evaluation and follow-up of active lymphocytic or granulomatous inflammatory processes such as sarcoidosis or tuberculosis. Common Indications of gallium-67 imaging (2) Diagnosing vertebral osteomyelitis and/or disk space infection where Ga-67 is preferred over labeled leukocytes. Diagnosis and follow-up of medical treatment of retroperitoneal fibrosis. Evaluation and follow-up of drug-induced pulmonary toxicity (e.g. Bleomycin, Amiodarone) Sarcoidosis Gallium Tumor Imaging Gallium tumor localization is likely multifactoral, but in part related to leaky capillary membranes in tumors, and the presence of iron-binding proteins such as ferritin which are found in increased concentrations in tumors. Bronchogenic carcinoma Squamous cell carcinoma has the highest (gallium avidity). adenocarcinoma has the lowest detection rate. gallium has a overall sensitivity of about 90% for the detection of primary bronchogenic carcinoma. Lesions smaller than 1.5 cm are difficult to detect. Lack of gallium accumulation in a lesion is still associated with a 24% probability for malignancy. Hodgkin's lymphoma Overall sensitivity for detecting Hodgkins lymphoma is about 85%, with a specificity of 90%. Gallium scintigraphy can also be used to predict patient response to treatment after initiation of chemotherapy. nodal uptake of tracer in the neck and mediastinum in this patient with Hodgkins disease. Non-Hodgkins Lymphoma Gallium sensitivity is reported to be better than 85% for high grade tumors. Sensitivity for low grade (slow growing) tumors is poor. A persistently positive Ga-67 exam after one cycle of treatment or at midtreatment for nonHodgkins lymphoma is associated with a higher likelihood for treatment failure, while a negative scan implies a favorable prognosis.